Optinose Announces Incentive Grants Under Nasdaq Listing Rule 5635(c)(4)

YARDLEY, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) — OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the The company granted non-qualified stock option awards to purchase a total of 185,000 shares of common stock to eight new employees as incentive material for accepting employment with OptiNose. The stock option awards were granted outside of the OptiNose, Inc. 2010 Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Stock options were granted to new employees on their respective hire dates (October 7, 2024 and October 14, 2024) with an exercise price equal to the closing price of the company’s common shares as reported by Nasdaq on the date of grant ($0.71 per share, on both dates).

The share purchase options have a term of 10 years and are exercisable in four years, with a quarter of the shares underlying the purchase option exercisable on the first anniversary of the grant date and the remainder exercisable in thirty-six equal monthly installments from then. The vesting of stock options is subject to continued service to the company until the applicable vesting date.

About Optinos
Optinose is a specialized pharmaceutical company focused on meeting the needs of patients treated by otolaryngologists and allergy sufferers. To learn more, visit www.optinose.com or follow us on Twitter and LinkedIn.

Optinose Investor Contact
Jonathan Neely
[email protected]
267.521.0531